



**Lee's Pharmaceutical Holdings  
Limited**  
李氏大藥廠控股有限公司

## **Lee's Pharm Accredited "Asia's Best Companies 2010 – (China) Best Small Cap" Ranked 2<sup>nd</sup>**

[8 June 2010 - Hong Kong] Lee's Pharmaceutical Holdings Limited ("Lee's Pharmaceutical" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, has been honoured outstanding achievement in ranking No. 2 of (China) Best Small Cap in the Asia's Best Companies Poll conducted by the leading regional financial magazine FinanceAsia showing the extensive recognition in the investment community of its seasoned management and effective corporate governance.

The Asia's Best Companies Poll invited investors and analysts from Asian countries and regions including mainland China, Hong Kong, India, Malaysia, Singapore and South Korea to evaluate companies according to various aspects such as management, corporate governance, investor relation, corporate social responsibility, dividend policy, etc. As a result, Lee's Pharm accredited Ranked 2<sup>nd</sup> of (China) Best Small Cap.

**Dr. Benjamin Li, CEO of the Group** said, "We are glad to receive this award. Lee's Pharm is constantly enhancing its seasoned management and stringent governance standards to offer the best returns for shareholders. These honours are clear recognition of our achievement from investors and analysts which drives the Group moving forward. Lee's Pharm was listed in the Main Board of Hong Kong Stock Exchange of Hong Kong Limited on 14 May this year. We will try our best in future to broaden the Group's growth opportunities with an objective to create the optimal returns to our investors."

~ End ~

### **Information about Lee's Pharmaceutical Holdings Limited**

**Lee's Pharmaceutical Holdings Limited**, a biopharmaceutical company, was successfully listed on the Growth Enterprise Market (GEM) of the Stock Exchange of Hong Kong Limited in 2002, with over 15 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing and sales and marketing in China with global perspective and it currently markets nine products in China. The Group focuses on many different areas such as cardiovascular diseases, dermatology, oncology, gynecology and others with more than 22 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies. Besides, the Group was listed in the Main Board of Hong Kong Exchange Limited on 14 May 2010.